Key Takeaways

• Lauxera Capital Partners has raised over €400 million for its second Healthtech growth fund, Lauxera Growth II, aiming to support European healthtech innovations.
• The fund has already invested in Acandis and Antaros Medical, focusing on neurovascular devices and AI-driven clinical trial technologies, respectively.
• Lauxera differentiates itself by providing operational support to portfolio companies, facilitating their growth in the U.S. market and beyond.

Fund Overview

Lauxera Capital Partners, with locations in Paris and San Francisco, has successfully raised over €400 million for its second Healthtech growth fund, Lauxera Growth II. This milestone was achieved rapidly and reflects the firm’s commitment to elevating Europe’s healthtech innovators to global market prominence through an active, operationally-driven investment strategy.

Established in 2020 by Samuel Levy, a physician and entrepreneur, Pierre Moustial, an experienced pharmaceutical executive, and Alex Slack, a healthcare investment expert, Lauxera combines deep medical knowledge with significant industry leadership and investment experience across both Europe and the U.S.

Pierre Moustial, Co-Founding Partner, highlighted the impressive fundraising success amid challenging market conditions, stating that it underscores investor confidence in Lauxera’s vision. The firm’s goal is to create transatlantic collaborations that facilitate the emergence and scaling of impactful healthtech solutions, leveraging its unique team dynamics and geographical advantages.

Lauxera Growth II has already made notable investments, including a €50 million stake in Germany’s Acandis, which specializes in advanced neurovascular devices for stroke and aneurysm treatment, with a manufacturing presence in over 60 countries. Another investment is in Sweden’s Antaros Medical, known for its AI technology that enhances clinical trial efficiencies for conditions like obesity and immunology.

Setting itself apart from many European funds that typically adopt an early or passive investment approach, Lauxera emphasizes robust operational support for its portfolio companies. This includes assistance in navigating the intricacies of U.S. regulations and scaling their operations internationally. Such support has proven beneficial, exemplified by the success of OrganOx, a previous portfolio company that was acquired by Japan’s Terumo group for $1.5 billion in 2025.

Lauxera reviews more than 1,000 investment opportunities annually, with a successful track record that includes businesses like Natural Cycles, an FDA-approved non-hormonal contraception app. Their investment model is resonating well among investors and entrepreneurs eager to extend their reach beyond fragmented European markets.

Looking ahead, Lauxera Growth II remains open to new investors and is set to announce a significant third investment soon. The fund aims to target sectors poised for large-scale innovation, including AI diagnostics, smart medical devices, and platforms that enhance healthcare delivery.

The content above is a summary. For more details, see the source article.